We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

MorphoSys Initiates Phase 2/3 B-MIND trial with MOR208 in DLBCL

News   Sep 06, 2016

 
MorphoSys Initiates Phase 2/3 B-MIND trial with MOR208 in DLBCL
 
 
Advertisement
 

RELATED ARTICLES

Simpler, High-Accuracy Method Detects Rare Circulating Tumor Cells

News

Researchers have demonstrated the effectiveness of a new machine learning technique to analyze the presence of rare circulating tumor cells in blood.

READ MORE

Accelerating Progress in Preventing Resistance to Anticancer Drugs

News

Researchers have developed new models to study the molecular characteristics of lung and pancreatic tumors that are driven by mutations in the NTRK1 gene.

READ MORE

Only Around 60% of Recovered COVID-19 Patients Develop Protective Antibodies

News

Scientists have found that only around 60% of patients who have had COVID-19 and recovered from it develop protective antibodies. They also showed that some antibodies even "assist" the virus in infecting host cells.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE